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Abstract
Background: Heat-shock protein B1 (HSPB1) is among the most well-known and versatile member of the evolutionarily
conserved family of small heat-shock proteins. It has been implicated to serve a neuroprotective role against various
neurological disorders via its modulatory activity on inflammation, yet its exact role in neuroinflammation is poorly
understood. In order to shed light on the exact mechanism of inflammation modulation by HSPB1, we investigated the
effect of HSPB1 on neuroinflammatory processes in an in vivo and in vitro model of acute brain injury.
Methods: In this study, we used a transgenic mouse strain overexpressing the human HSPB1 protein. In the in vivo
experiments, 7-day-old transgenic and wild-type mice were treated with ethanol. Apoptotic cells were detected using
TUNEL assay. The mRNA and protein levels of cytokines and glial cell markers were examined using RT-PCR and
immunohistochemistry in the brain. We also established primary neuronal, astrocyte, and microglial cultures which were
subjected to cytokine and ethanol treatments. TNFα and hHSPB1 levels were measured from the supernates by ELISA, and
intracellular hHSPB1 expression was analyzed using fluorescent immunohistochemistry.
Results: Following ethanol treatment, the brains of hHSPB1-overexpressing mice showed a significantly higher mRNA level
of pro-inflammatory cytokines (Tnf, Il1b), microglia (Cd68, Arg1), and astrocyte (Gfap) markers compared to wild-type brains.
Microglial activation, and 1 week later, reactive astrogliosis was higher in certain brain areas of ethanol-treated transgenic
mice compared to those of wild-types. Despite the remarkably high expression of pro-apoptotic Tnf, hHSPB1-overexpressing
mice did not exhibit higher level of apoptosis. Our data suggest that intracellular hHSPB1, showing the highest level in
primary astrocytes, was responsible for the inflammation-regulating effects. Microglia cells were the main source of TNFα in
our model. Microglia isolated from hHSPB1-overexpressing mice showed a significantly higher release of TNFα compared to
wild-type cells under inflammatory conditions.
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Conclusions: Our work provides novel in vivo evidence that hHSPB1 overexpression has a regulating effect on acute
neuroinflammation by intensifying the expression of pro-inflammatory cytokines and enhancing glial cell activation, but not
increasing neuronal apoptosis. These results suggest that hHSPB1 may play a complex role in the modulation of the ethanol-
induced neuroinflammatory response.
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Background
Neuroinflammation plays a central role in the pathophysi-
ology of most neurological diseases. The activation of
astro- and microglia cells, and their subsequent produc-
tion of cytokines and chemokines are the main character-
istics of neuroinflammation. Inflammation in the brain is
primarily associated with the process of neurodegenera-
tion, as it is initiated in order to aid the repair of the dam-
aged brain area. However, in the case if it becomes
dysregulated, a chronic inflammation could appear which
further aggravates tissue damage. Therefore, the tight
regulation of the neuroinflammatory response during
neuronal tissue damage is crucial in preventing or at least
in reducing the negative effects of chronic inflammation
[1]. Heat-shock proteins (HSPs) could be one of the po-
tential candidates for such an inflammation-regulating
role, as they show a rapid induction under stress condi-
tions, they promote cell survival under these conditions,
and their modulatory effects on inflammatory processes
are well described [2].
Heat-shock protein B1 (HSPB1, HSP27/25) is one of
the most well-studied members of the evolutionarily
conserved small heat-shock protein family. These ATP-
independent chaperon proteins are characterized by low
molecular weight between 16 and 40 kDa, and a con-
served C-terminal α-crystallin domain. As molecular
chaperones, small heat-shock proteins have an important
role in maintaining the normal cellular protein homeo-
stasis by binding to partially denatured proteins, thereby
preventing their irreversible aggregation [3]. In the brain,
HSPB1 is the most abundant in astrocytes under physio-
logical conditions and it is even more elevated in re-
sponse to various stress conditions, such as increased
temperature or oxidative stress [4, 5]. Increased astro-
glial expression of HSPB1 was also detected after transi-
ent focal ischemia and in neurodegenerative disorders
associated with pathological protein inclusions, such as
tauopathies or Alzheimer’s disease [4, 6–8]. This line of
observations suggests that HSPB1 might also play a role
in reactive astrogliosis. Compared to astrocytes, HSPB1
is present in neurons to a lesser extent, although it was
also described to be upregulated in pathological and
under stress conditions [4, 9, 10]. In microglia, HSPB1 is
present only in negligible amounts but following hyper-
thermia, it showed an elevated expression [11].
Besides its well-described role as a chaperon, HSPB1 is
also associated with neuroinflammation through several
mechanisms. HSPB1 can help to maintain the integrity
of cytoskeletal networks through its association with
various cytoskeletal filaments, such as the glial fibrillary
acidic protein (GFAP), vimentin (Vim), or neurofilament
[12, 13]. HSPB1 can also interact with several compo-
nents of the apoptotic pathways and exert a strong anti-
apoptotic function [14]. Moreover, it can modulate the
release of cytokines from various cells; however, a multi-
tude of effects can be observed in different studies in
that regard. There has been an observation that de-
scribed an HSPB1-dependent interleukin-10 (IL-10) in-
crease and an associated anti-inflammatory response
[15]. However, another study pointed towards a more
pro-inflammatory role for HSPB1 as it was observed to
induce the production of IL-8 and reduce the expression
of anti-inflammatory transforming growth factor-β1
(TGF-β1) and the cluster of differentiation 40 (CD40)
ligand in astrocytes in vitro [16]. In addition, HSPB1 is
described to regulate the activation of the nuclear factor
kappa B (NFκB) pathway. Recently, intracellular HSPB1
has been demonstrated to promote the degradation of
IkappaB kinase-β resulting in an inactive state of NFκB
and a subsequent decrease in tumor necrosis factor-α
(TNFα) production in microglial cells [17]. However, in
a macrophage culture, extracellular HSPB1 treatment
was observed to activate the NFκB pathway via the deg-
radation of the inhibitor of nuclear factor-kappa B-α
(IκBα), thereby upregulating both pro- and anti-
inflammatory factors, such as IL1b, TNF, IL-10, and the
granulocyte-macrophage colony-stimulating factor [18].
Moreover, HSPB1 expressed in endothelial cells of the
brain microvasculature contributes to an indirect protec-
tion against neuroinflammation. HSPB1 was described
to ameliorate the impairment of the blood-brain barrier,
and by this decreasing the influx of peripheral immune
cells into the brain parenchyma after ischemic injury
[19]. Overall, a growing number of evidence indicates
that HSPB1 can affect the inflammation-related pro-
cesses in several ways, but it seems to induce diverse ef-
fects depending on the cell type and the extra- or
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intracellular presence of the protein. Despite the diver-
sity of the observed actions for HSPB1 in the central
nervous system, the inflammation modulatory effects of
this protein would require further clarification. In
addition, there is a lack of comprehensive in vivo studies
investigating the impact of HSPB1 on multiple compo-
nents of inflammation within the CNS.
In this study, we aimed to test the hypothesis whether
HSPB1 is involved in the regulation of cytokine expres-
sion, gliosis, and apoptosis in ethanol-induced acute neu-
roinflammation. We analyzed the inflammation-related
processes using our previously generated human HSPB1
(hHSPB1)-overexpressing transgenic mouse strain [20], as
well as using primary cell cultures isolated from the trans-
genic mouse model. Ethanol treatment is a suitable
method for modeling the sterile inflammatory environ-
ment that serves as a central disease-promoting mechan-
ism in many neurological disorders. In our in vivo
experiments, we used early postnatal acute ethanol expos-
ure because, due to the particularly high sensitivity of the
developing brain to alcohol toxicity, even a single ethanol
treatment leads to robust neurodegeneration, which is ac-
companied by neuroinflammatory processes, including
cytokine release and glial cell activation [21, 22]. Accord-
ingly, with this method, we were able to induce neuroin-
flammation rapidly in the brains of 7-day-old hHSPB1-
overexpressing transgenic and wild-type mice and to in-
vestigate the possible immunomodulatory effects of
hHSPB1 overexpression in this sterile inflammatory mi-
lieu. hHSPB1-overexpressing mice showed enhanced ex-
pression of pro-inflammatory cytokines Tnf and Il1b as
well as increased immunoreactivity of astrocyte and
microglial activation markers in response to ethanol-
induced acute brain injury, whereas they exhibited a non-
significant trend of decreased apoptosis. In addition,
in vitro results showed that the release of hHSPB1 from
the cells is minimal even after stress treatment. Therefore,
we suggest that the intracellular form of hHSPB1 is re-
sponsible for the observed inflammation-regulating ef-
fects, showing a significantly increased expression in
primary astrocytes after cytokine and ethanol treatment.
Moreover, microglia seemed to be the main source of
pro-inflammatory cytokines in vitro, since the highest
TNFα response to cytokine treatment was detected in
the supernates from microglia cultures from hHSPB1
transgenic animals. Taken together, we found that the
ethanol-induced neuroinflammatory processes were
aggravated in our HSPB1-overexpressing mice includ-
ing the pro-inflammatory cytokine expression and
glial cell activation, while we could not detect the fur-
ther increase of the inflammation-related neuronal
damage in these animals, suggesting that HSPB1 has





The study has been carried out according to the EU Dir-
ective 2010/63/EU and was approved by the regional
National Food Chain Safety Agency and Animal Health
Directorate (Csongrad-county, Hungary) under the pro-
ject license XVI/4136/2014. Mice were housed in groups
of two to three under standard conditions (24 °C, 12 h of
light-dark cycle) with food and water available ad libi-
tum. Seven-day-old hHSPB1 transgenic mice and wild-
type littermates were used for the studies. The hHSPB1-
overexpressing transgenic line was previously established
by our group on a homogenous C57BL/6 genetic back-
ground [20].
Ethanol treatment
Neurodegeneration was induced in 7-day-old wild-type
and hHSPB1-overexpressing transgenic mice by the sub-
cutaneous injection of 20% ethanol solution as described
earlier in Ikonomidou et al. [21]. Ethanol was adminis-
tered in two equal doses of 2.5 g/kg body weight within 2
h (at zero and at the 2nd hour), resulting in a total dose of
5 g/kg. Control pups were treated with physiological sa-
line. After cervical dislocation and decapitation, brains
were removed at 7 h/24 h/1 week after the second injec-
tion and processed as follows: the dissected brains were
embedded in optimal cutting temperature (OCT) com-
pound (Tissue-Tek, Sakura Finetek, CA, USA) for cryostat
sectioning and to carry out the terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay; for
immunohistochemistry, brains were immersion-fixed in
3% paraformaldehyde (PFA)-0.1M phosphate buffer solu-
tion; the brains were further homogenized in AccuZol Re-
agent for RNA isolation or in radioimmunoprecipitation
assay (RIPA) buffer for protein isolation. At the same time,
small tail biopsies were taken for subsequent genomic
DNA isolation and genotype determination.
hHSPB1 Western blot analysis
Protein level of transgenic human HSPB1 was deter-
mined from whole-brain homogenates of 7-day-old mice
(n = 3 mice per group). Brains were homogenized in 1
ml RIPA buffer containing 2 mM phenylmethylsulfonyl
fluoride and 2mMN-ethylmaleimide. After centrifuga-
tion (13,000g for 25 min at 4 °C), protein concentrations
were measured in the supernates at 280 nm using a
NanoDropND-1000 spectrophotometer (Nanodrop, DE,
USA). Five milligram per milliliter samples were mixed
with sample buffer containing sodium dodecyl sulfate
(SDS), glycerol, β-mercaptoethanol, and bromophenol
blue, and incubated at 95 °C for 5 min. Protein samples
(50 μg) were loaded into a 15% SDS-polyacrylamide gel
and samples were run at 80 V for 2 h in 1× SDS-PAGE
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running buffer. Then, proteins were transferred to poly-
vinylidene difluoride membranes (Pall Corporation, NY,
USA), were submerged in 1× transfer buffer, and run at
200 mA for 1 h on ice. Subsequently, membranes were
incubated in phosphate-buffered saline with Tween 20
(PBST) containing 5% nonfat milk powder for 1 h at
room temperature. The following primary antibodies
were used in the study: rabbit anti-hHSPB1 (O/N at
4 °C, Stressgen - Enzo Life Sciences, NY, USA, no cross-
reactivity with mouse HSPB1) and rabbit anti-actin (2 h
at room temperature, Sigma-Aldrich Ltd, Budapest,
Hungary). The secondary antibody used was horseradish
peroxidase–conjugated goat anti-rabbit (Jackson Immu-
noResearch Europe Ltd., Cambridgeshire, UK) (see Table
S1 for details of antibodies). Afterwards, membranes
were incubated with a chemiluminescent detection re-
agent (Luminata Forte Western HRP Substrate, Merck
Millipore, MA, USA) for 2 min and blots were developed
manually on X-ray films. Quantification of the results
was performed using the open-access ImageJ software.
mRNA isolation and reverse transcription
mRNA was isolated from whole brains of the mice. Ho-
mogenized tissue was mixed with AccuZol Reagent (Bio-
neer, South Korea), by adding 1 ml to each tissue
sample. Subsequently, 200 μl chloroform was added to
the samples followed by incubation on ice for 5 min.
Phases were separated by centrifugation at 13,000g for
15 min at 4 °C, and the aqueous phase was separated
from the organic phase from where the RNA was precip-
itated with 100% isopropyl alcohol during incubation for
10 min at − 20 °C. After centrifugation for 10 min at 13,
000g at 4 °C, the RNA pellets were washed with 80%
ethanol and the samples were centrifuged for 5 min at
13,000g at 4 °C. The RNA pellets were dissolved in
RNase-free water and cleaned by using Nucleo Spin
mRNA Clean-Up columns (Macherey-Nagel, Düren,
Germany). Samples were treated with DNase and were
eluted from the membrane with RNase-free water. Con-
centrations of the samples were measured at 230 nm
using a spectrophotometer (NanoDrop ND-1000, Nano-
drop, DE, USA). mRNA samples were converted to
cDNA using reverse transcription (High Capacity cDNA
Reverse Transcription Kit, Applied Biosystems, CA,
USA) according to the manufacturer’s instructions.
Real-time PCR analysis
Real-time (RT)-PCR was performed to analyze the level
of hHSPB1, cytokines, and glial markers. Gene-specific
primers are listed in Table S2. Each reaction was per-
formed in a total volume of 20 μl containing 10 μl of
Power SYBR Green PCR Master Mix (Applied Biosys-
tems, CA, USA), 1 μl of 5 pmol/μl primer mix (forward
+ reverse), and 9 μl of cDNA sample. The amplification
was carried out on a RotorGene 3000 instrument (Cor-
bett Research, Australia) with the following cycling pa-
rameters: heat activation at 95 °C for 10 min; followed by
45 cycles of denaturation at 95 °C for 15 s, annealing at
56 °C for 15 s, and extension at 60 °C for 40 s. Fluores-
cent signals were collected after each extension step at
72 °C and at the end, the registration of the melting
curve was performed between 50 and 95 °C. Expression
level of the target genes was normalized to an endogen-
ous control (glyceraldehyde 3-phosphate dehydrogenase,
Gapdh). Relative expression of the target genes com-
pared to the untreated wild-type animals was calculated
using the ΔΔCt method (n = 8 mice per group at 24 h;
n = 3 mice per group at 7 h and 1 week).
TUNEL assay
To assess the level of apoptotic cell death, TUNEL assay
was used, which labels the fragmented DNA. Brains
were embedded in OCT compound, then 10-μm sagittal
frozen sections were prepared. Sections were post-fixed
in 4% paraformaldehyde in phosphate-buffered saline
(PBS) solution (pH = 7.4) for 20 min. Following a 30-min
PBS rinse, sections were blocked in 3% H2O2 in metha-
nol for 10 min, then they were permeabilized with a so-
lution of 0.1% Triton X-100 and incubated in 0.1%
sodium citrate for 2 min. After washing with PBS, 50 μl
of TUNEL reaction mixture was added to each sample
(In situ Cell Death Detection Kit, POD, Roche Applied
Science, IN, USA) and the sections were incubated for 1
h at 37 °C in a humidified atmosphere. Under the same
circumstances, the sections were incubated with
Converter-POD solution for 30 min, then washed in
PBS, followed by a 10-min signal conversion with a per-
oxidase reagent. The red apoptotic cells were detected
under a light microscope. For quantitative comparison,
the TUNEL-positive cells were counted in fifteen fields
of view of each brain section (n = 6 mice per group).
Fluorescent immunohistochemistry
Double immunostaining was performed to study the
expression pattern of hHSPB1. After washing in PBS, 30-
μm-thick frozen sagittal brain sections were permeabilized
and blocked with 0.2% Triton X-100 and 3% bovine serum
albumin (BSA) in PBS for 1 h at room temperature. Then
the sections were incubated overnight at 4 °C with the fol-
lowing primary antibodies: goat anti-IBA1 (ionized cal-
cium–binding adaptor molecule 1, Abcam, Cambridge,
UK), mouse anti-GFAP (Sigma-Aldrich Ltd, Budapest,
Hungary), mouse anti-NEUN (neuronal nuclei, Merck
Millipore, MA, USA), and rabbit anti-hHSPB1. Appropri-
ate secondary antibodies were applied for 2 h: Alexa
Fluor-488–conjugated rabbit anti-goat (Jackson Immu-
noResearch Europe Ltd., Cambridgeshire, UK); FITC-
conjugated goat anti-mouse (Sigma-Aldrich Ltd, Budapest,
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Hungary); Alexa Fluor-647–conjugated goat anti-rabbit
(Thermo Fisher Scientific, MA, USA) (Table S1). Cell nu-
clei were counterstained with 4′,6-diamidino-2-phenylin-
dole (DAPI) (Sigma-Aldrich Ltd, Budapest, Hungary), at
the concentration of 0.5 μg/ml for 5 min. Immunostain-
ings were examined with a confocal laser scanning micro-
scope (Olympus Fluoview FV1000, Olympus Life Science
Europa GmbH, Hamburg, Germany).
Peroxidase immunohistochemistry
To analyze the activation of glial cells, brain sections were
labeled with microglia and astrocyte markers. The brain
region–specific expression pattern of the transgenic
hHSPB1 protein was also examined with this method.
First, the brain sections were treated with 20% methanol
and 3% H2O2 for 15min to deactivate endogenous peroxi-
dases. The sections were washed in PBS then blocked for
2 h at room temperature using 2% normal rabbit or horse
serum and 0.3% BSA in PBS. Then the sections were incu-
bated with rabbit anti-hHSPB1, mouse anti-GFAP, or goat
anti-IBA1 primary antibodies overnight at 4 °C. Subse-
quently, sections were incubated with the appropriate sec-
ondary antibodies: peroxidase-labeled goat anti-rabbit,
peroxidase-conjugated rabbit anti-mouse (Chemicon-
Merck Millipore, MA, USA), or biotinylated donkey anti-
goat (Jackson ImmunoResearch Europe Ltd., Cambridge-
shire, UK) for 2 h (Table S1). The sections were then
incubated with the chromogen substrate, 3,3′-diamino-
benzidine (DAB) (Sigma-Aldrich Ltd, Budapest, Hungary)
at the concentration of 10mg/ml for 15min, and the solu-
tion was supplemented with 1% nickel chloride. For IBA1
staining, an avidin-biotin (VECTASTAIN Elite ABC Per-
oxidase Kit, Vector Laboratories, CA, USA) treatment was
applied for 2 h at room temperature as a signal amplifica-
tion step before visualizing the immunoreaction with
DAB. The immunostained sections were digitally scanned
using a slide scanner (Mirax Midi, 3DHistech Ltd.,
Budapest, Hungary) (n = 3 mice per group and 3 sections
per animal). Images were analyzed with the Pannoramic
Viewer 1.15.4; CaseViewer 2.1 and QuantCenter; and His-
toQuant module softwares (3DHistech Ltd., Budapest,
Hungary). Each region of interest was manually outlined,
then followed by automated detection of relative areas of
immunopositivity. Results are given in percentage of the
immunopositive areas compared to the outlined areas
(relative area).
Automated analysis of microglial morphology with deep
learning approach
Morphological categorization The activity state of
microglia can be well characterized by their morphology,
based on which microglia were classified into three sub-
types: ramified (first class), intermediate (second class),
and amoeboid (third class) [23, 24]. The ramified
morphology of resting microglia is characterized by a
small cell body and branching, long, thin processes
extending far from the cell body (Fig. S1a). Cells clas-
sified into intermediate and amoeboid groups can be
considered activated. The former is characterized by
having an enlarged cell body and numerous thick,
shortened processes which are still branching, while
the latter is characterized by a large cell body which
is completely round or has a few very short and thick
primary processes (Fig. S1b).
Annotation procedure Manual annotations were per-
formed using the AnnotatorJ software [25]. In total,
5883 cells on 232 images were annotated independently
by two experts. Each annotated object in the set contains
an associated class label and a bounding rectangle that
was drawn around it. The total number of classes is 3.
The number of the annotated cells in the first class was
2961 and 1461-1461 in the second and third. Rectangle
size can vary and they can intersect each other.
For performance evaluation, 30 images with a total of
~ 800 cells were selected. This validation set was anno-
tated by both of the experts. Performing this annotation
at two different time points, we measured the intraex-
pert accuracies.
Evaluation with deep learning Training the model:
pytorch [26], a Python-based deep learning package was
used to detect microglia (we used Python 3.6). We
trained multiple models based on two different architec-
tures, namely the yolov3-SPP [27] and CSPResNext50-
PANet-SPP [28]. To make the training robust, the train-
ing data was augmented using random affine transfor-
mations. We were using ADAM (Adaptive Moment
Estimation [29]) optimizer with a base learning rate of
0.001. Because for such data there are no pretrained
weights available, we used random initialization. The
number of epochs for each setup was 2000. This resulted
in 0.594 as the best mAP (mean average precision) for
yolov3-SPP and 0.593 as the best mAP for CSPRes-
Next50-PANet-SPP. The training was performed on a
GPU cluster with a 2.10 GHz Intel(R) Xeon(R) ES-2620
CPU, 32 GB memory, and NVIDIA Titan Xp graphics
card and for both cases took roughly 72 h.
Microglia detection with classification We selected
the yolov3-SPP model for the evaluation part because it
resulted both statistically and visually in better results.
To evaluate the performance of the proposed deep
learning model, we measured precision, recall, and F1
score of two different annotators. The object matching
between the detection and classification results and the
ground truth was done manually by an expert. We
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considered a bounding box detection to be correct (true
positive, TP) when it fully contained a cell; otherwise, it
was considered as false positive (FP). When the detec-
tion algorithm was not able to find an object that was
listed in the ground truth, that sample was treated as
false negative (FN). Based on these conditions, we calcu-
lated the precision (P) = TP / (TP + FP); recall (R) = TP /
(TP + FN); F1 score (F1) = 2 * P * R / (P + R); and detec-
tion accuracy (DA) = TP / (TP + FP + FN).
To inspect the accuracy of the classification part, we
have checked all the images selected for the evaluation.
As the detection accuracy was already calculated, we su-
pervised the predicted class labels for each object. Based
on the correctly (C) and incorrectly (IC) predicted class
labels, we calculated the classification accuracy (CA) =
(C) / (C + IC) (Fig. S1c).
For the final detection result, we evaluated four different
comparisons. First, we measured self-accuracy of the hu-
man experts. This involves intra- and interexpert accur-
acies. We measured intraexpert accuracy by multiple
annotations of the same images made by the same expert.
We did this by annotating the same images with 2 weeks
time difference. The intraexpert accuracies resulted in
97.4% accuracy (precision = 0.985, recall = 0.989, F1
score = 0.987) and 97.8% accuracy (precision = 0.984, re-
call = 0.993, F1 score = 0.988). Meanwhile, interexpert
accuracy is the comparison of the annotations made by
two experts on the same test set. This observation has
reached 92.9% accuracy (precision = 0.949, recall = 0.977,
F1 score = 0.963). In these cases, we used the test set made
by the first annotator as the ground truth. Finally, we
compared the ground truth to the predicted bounding
boxes. This performed almost as well as the annotators
and reached a surprising 94.4% accuracy (precision =
0.966, recall = 0.977, F1 score = 0.971) (Fig. S1d).
For the final classification result, we evaluated four dif-
ferent comparisons, following the same scheme as for
the detection part. The intraexpert accuracies reached
97% accuracy and 98.1% accuracy. The interexpert ac-
curacy resulted in 90.5% accuracy. And the final com-
parison achieved 90.1% accuracy.
In vitro experiments
Preparation of primary cultures
The isolation of primary neurons was carried out ac-
cording to Pacifici and Peruzzi [30] with some modifica-
tions. Primary cortical neurons were obtained from
hHSPB1 transgenic mice and wild-type littermates on
the 17th embryonic day. Briefly, embryos were washed
in cold dissection medium, then the whole brain was ex-
tracted and was placed into an ice-cold Hibernate E
medium (BrainBits, IL, USA). Cerebral cortices were iso-
lated, while meninges were removed from the surface,
and cortices were washed 3 times with Hibernate E, then
were enzymatically digested with TrypLE (Gibco, Life
Technologies, CA, USA) at 37 °C for 10 min. Next, the
digested cortices were washed 3 times with Hibernate E
and were homogenized in Neurobasal/B27 complete
medium (Gibco, Life Technologies, CA, USA) containing
200 mM Glutamax (Gibco, Life Technologies, CA, USA)
with 18-G and 20-G needles (Braun, Germany). Finally,
the suspension was diluted with Neurobasal/B27
complete medium, and cells were counted using Count-
ess Automated Cell Counter (Thermo Fisher Scientific,
MA, USA). Cells were plated on poly-D-lysine-coated
96-well plates at the density of 2 × 104 cells/well. Primary
neurons were cultured in an incubator with 5% CO2 and
37 °C for 5 days.
Primary mouse glial cells were isolated and cultured as
described in Lenárt et al. [31]. Briefly, forebrains without
the cerebellum and the bulbus olfactorius were obtained
from 4-day-old wild-type and hHSPB1 transgenic mice
and placed into ice-cold PBS. Meninges were removed
from the surface of the brains by using a fine forceps
and sterile filter paper. Little pieces of cortices were pi-
petted to 50-ml tubes and then the tissue was mechanic-
ally dissociated using a long and thin needle (21G 4 ¾,
Braun, Germany). Isolated cells were plated onto un-
coated T25 flasks (Corning Costar Co., MA, USA) and
cultured in low-glucose Dulbecco’s modified Eagle’s
medium (Gibco, Life Technologies, CA, USA) containing
10% fetal bovine serum (Sera Plus, Pan Biotech, Aiden-
bach, Germany) and gentamycin (Sigma-Aldrich Ltd,
Budapest, Hungary) at the concentration of 50 μg/ml
and were cultured until confluency before used for ex-
periments. Medium was changed every 2 days.
Microglial cells were isolated from the surface of pri-
mary astroglia cultures [32]. Here astroglia were not pas-
saged after reaching confluency but kept in the flask for
longer periods. After 10 days, microglia cells migrate to
the top of the confluent astroglia layer and start to
round up on the surface. After gently tapping the flasks,
the detaching microglia cells were collected and plated
in astroglia culture medium onto poly-L-lysine-coated
96-well plates with a cell density of 2 × 104 cells/well.
With this method, additional microglia cells were col-
lected every second day for up to a week from the sur-
face of the glial layer. Half of the medium was changed
every day. Microglia cells received 50% glia cell–condi-
tioned medium from day 3 and were cultured for 7 days
before treatments.
Assessment of the purity of the isolated primary cell
cultures by immunostaining
In order to determine the purity of primary neuron,
astroglia, and microglia cultures, cells were passaged
either to thin-bottom 96-well plates (Corning Costar
Co., MA, USA) or to coverslips (VWR, PA, USA) and
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stained for specific markers. Glial cells and microglia
were cultured on poly-L-lysine-coated glass coverslips
and in 96-well plates along with neurons. Following
the regular permeabilization and blocking steps (for
this, see Methods’ section “Fluorescent immunostain-
ing”), cells were stained for specific markers. To
evaluate the purity of the neuronal cultures, cells
were double-labeled for neuronal marker micro-
tubule–associated protein-2 (chicken anti-MAP2,
Abcam, Cambridge, UK) and astrocyte marker GFAP
(mouse anti-GFAP). Primary isolated astroglia cultures
can be contaminated by microglia cells and vice versa;
therefore, to assess the level of astroglia and microglia
purity, we stained for GFAP and for the microglial
marker IBA1 (goat anti-IBA1) (Table S1). The follow-
ing secondary antibodies were used: Alexa Fluor-594–
conjugated donkey anti-chicken (Jackson ImmunoRe-
search Europe Ltd., Cambridgeshire, UK); Alexa
Fluor-488–conjugated donkey anti-mouse (Life Tech-
nologies, Invitrogen, USA), Alexa Fluor-488–conju-
gated donkey anti-goat (Life Technologies, Invitrogen,
USA), Dylight 549–conjugated goat anti-mouse (Jack-
son ImmunoResearch Europe Ltd., Cambridgeshire,
UK) (Table S1). After mounting the samples (Fluoro-
mount-G; Southern Biotech, AL, USA), pictures were
taken at random positions (at least 3 images/sample),
using fluorescent confocal laser scanning microscopes:
Olympus Fluoview FV1000 (Olympus Life Science
Europa GmbH, Germany) and Leica SP8 Confocal
Microscope (Leica Microsystems, Germany). Cell nu-
clei were counted for both stainings and an image
quantitation was performed where percentages of the
marker positive cells were given normalized to the
total cell number (n = 3–11).
Treatments and collection of supernates
Primary neurons were treated 5 days after the isolation
with human TNFα and IL-1β (10 ng/ml each) and 200
mM EtOH. The treatments on primary neurons were
performed in 96-well plates in 50 μl/well Neurobasal/
B27 complete medium (Gibco, Life Technologies, CA,
USA). After 24 h of treatment, cell culture supernates
were collected, an 3-3 wells were pooled, centrifuged at
510g to remove any contaminating cells or debris, and
then stored at − 80 °C. Meanwhile, cells were fixed with
4% PFA for 20 min and then stored in 1× PBS at 4 °C for
immunofluorescent staining.
All treatments and supernate collection from primary
astroglia and microglia cells were performed similarly
except that a lower concentration of EtOH (50 mM) was
used in glial cell culture medium. After the treatment,
cell culture supernates were collected and stored at −
80 °C. Cells were fixed with 3% PFA for 15 min at room
temperature and then stored in PBS containing 0.1% so-
dium azide at 4 °C for immunofluorescent staining.
Fluorescent immunostaining
To analyze the expression pattern of hHSPB1, PFA-fixed
primary neuronal cells were permeabilized with 0.1% Tri-
ton X-100 for 10min. Cells were then blocked with 3%
BSA in PBS for 1 h and were incubated overnight with pri-
mary antibodies: chicken anti-MAP2 and rabbit anti-
hHSPB1. Subsequently, the cells were incubated with sec-
ondary antibodies: Alexa Fluor-594–conjugated donkey
anti-chicken and Alexa Fluor-488–conjugated goat anti-
rabbit (Thermo Fisher Scientific, MA, USA) for 45min
(Table S1). Cell nuclei were labeled with DAPI (Sigma-Al-
drich Ltd, Budapest, Hungary) at 0.5 μg/ml for 5min. The
stainings were examined with a Leica SP8 Confocal
Microscope (Leica Microsystems, Germany).
To further assess the hHSPB1 expression, microglia and
astroglia cells were co-stained for their corresponding
markers and for hHSPB1. After PFA fixation,
permeabilization was carried out with 0.2% Triton X-100 in
PBS for 10min, followed by blocking with 2% normal horse
serum or 5% normal goat serum. Primary antibodies were in-
cubated overnight: goat anti-IBA1, mouse anti-GFAP, rabbit
anti-hHSPB1. Incubation with secondary antibodies Alexa
Fluor-488–labeled donkey anti-goat, Cy3-labeled sheep anti-
rabbit (Sigma-Aldrich Ltd, Budapest, Hungary), Dylight
A488–conjugated goat anti-rabbit (Jackson ImmunoResearch
Europe Ltd., Cambridgeshire, UK), and Dylight 549–conju-
gated goat anti-mouse lasted for 1 h. Hoechst dye 33342 was
used for nucleus staining (Table S1). After mounting the
samples (Fluoromount-G; Southern Biotech, AL, USA),
staining was examined by Olympus Fluoview FV1000 con-
focal laser scanning microscope (Olympus Life Science Eur-
opa GmbH, Hamburg, Germany).
The images were analyzed using the Matlab software
(MathWorks, Natick, MA, USA). An average threshold was
calculated for each staining using the images from the trans-
genic and wild-type animals. The binary images were deter-
mined by using the corresponding average threshold.
Objects with a size of less than 4 pixels were eliminated to re-
duce any false structures. The colocalization was received by
taking overlapping structures of the corresponding binary
images. The overall intensities were calculated using the final
binary images as masks on the original grayscale images. The
intensity values gained from astrocytes were normalized to
the pixel numbers from where the intensity data was col-
lected (n= 9–12 for GFAP in TG astrocytes; n= 14–15 for
GFAP in WT astrocytes; n= 10–11 for hHSPB1 in TG astro-
cytes). Due to the presence of astrocytes in neuronal culture,
which also highly express the transgene, HSPB1 intensity
values were obtained from neurons and normalized to the
pixel number of neuronal marker MAP2 (n= 12).
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Enzyme-linked immunosorbent assay analysis of cell culture
supernates
Concentrations of released hHSPB1 and TNFα in the
supernate of all three primary isolated cell cultures were
quantified using human HSPB1 ELISA kit (Enzo Life
Sciences, NY, USA) and mouse TNF alpha ELISA kit
(Life Technologies, Invitrogen, USA). Briefly, cell culture
supernates were collected and additional sample diluents
were added. For all cell types, samples from multiple ex-
periments were tested to create biological and technical
parallels (n = 2–3). We used 47 μl sample/well for the
mouse TNFα assay, and 95 μl sample/well for the
hHSPB1 assay. After the addition of supernates to the
wells, the assay was carried out according to the manu-
facturer’s instructions.
Statistical analysis
All data obtained in this experiment are expressed as
mean ± SEM. Statistical analysis was performed by two-
way analysis of variance (2-way ANOVA) followed by
Tukey post hoc test using the OriginPro8 software (Ori-
ginLab, MA, USA) and unpaired two-tailed t test using
GraphPad Prism software (GraphPad Software Inc., San
Diego, CA, USA). Data were considered statistically sig-
nificant at p < 0.05.
Results
Expression pattern of transgenic human HSPB1 in the
mouse brain
The expression of the transgenic hHSPB1 was studied in
the brain of 7-day-old mice using various methods.
Whole-brain homogenates were analyzed by Western
blotting (Fig. 1a, b) and RT-PCR (Fig. 1c). High expres-
sion of transgenic hHSPB1 was detected in transgenic
brains both at the protein and mRNA levels. hHSPB1
expression increased 24 h after ethanol treatment, espe-
cially in the hippocampal region and in the retrosplenial
cortex, as shown by our immunohistochemical analysis
(Fig. 1d). The cell-specific expression pattern of the
transgene was also monitored using NEUN-hHSPB1,
GFAP-hHSPB1, and IBA1-hHSPB1 fluorescent double
immunostainings (Fig. 1e). The NEUN-hHSPB1 double
immunostaining revealed the presence of the transgenic
hHSPB1 protein in neuronal cells. The GFAP immuno-
labeling colocalized with hHSPB1, indicating that
astrocytes also expressed the transgene. IBA1 immuno-
reactive microglia, however, showed no remarkable colo-
calization with hHSPB1.
Differences in the gene expression of pro- and anti-
inflammatory cytokines in hHSPB1 transgenic and wild-
type mouse brains
The expression level of cytokines as molecular markers
of inflammation was studied using semiquantitative RT-
PCR at different time points after ethanol treatment. In
nontreated transgenic mice, hHSPB1 overexpression
alone did not affect significantly the mRNA level of the
studied pro-inflammatory cytokines, whereas it contrib-
uted to a marked increase in gene expression after etha-
nol treatment. In response to ethanol, the level of Tnf
mRNA was elevated as early as 7 h, showing a threefold
(297%) increase in wild-type and a fourfold (413%) in-
crease in hHSPB1-overexpressing animals compared to
saline-treated controls (Fig. S2a). One day later, Tnf ex-
pression started to decrease in the wild-type animals but
still maintained a twofold (229%) increase compared to
the nontreated controls (Fig. 2a). However, in transgenic
animals, we detected a further elevation in the level of
Tnf mRNA, reaching a tenfold (1031%) increase in ex-
pression compared to untreated wild-types (Fig. 2a).
Similar changes were found in the expression level of
Il1b: it also increased in response to the ethanol treat-
ment; however, this had happened at a later time point.
One day after the treatment, it showed a twofold in-
crease in the wild-type animals, while in the transgenic
ones, we detected a much higher, a more than sevenfold
increase (706%, Fig. 2b). Another inflammation-inducing
cytokine, Il6, also showed a similar, but nonsignificant
trend towards increased expression in ethanol-treated
transgenic mice (Fig. 2c). Contrarily, in the case of anti-
inflammatory cytokines, we observed changes only in
the mRNA level of Tgfb, whereas the expression levels of
Il10 and Il4 remained unchanged in response to hHSPB1
overexpression as well as after ethanol treatment (Fig.
2d–f). In the nontreated group, the expression level of
the Tgfb was twice as high in hHSPB1-overexpressing
animals as in wild-type ones 24 h after saline injection
(Fig. 2d). One day after ethanol administration, the ex-
pression level of Tgfb showed a significant increase in
wild-type animals (233%), whereas in transgenic mice,
no further increase was detected. After 1 week, the gene
expression levels of the investigated cytokines decreased
to their original levels both in the wild-type and in the
transgenic brains (Fig. S2a-c).
Altered microglial activation in hHSPB1 transgenic brains
The expression level of the microglia-specific allograft
inflammatory factor 1 (Aif1, gene encoding protein
IBA1) was analyzed using RT-PCR. In the saline-treated
group, hHSPB1 transgenic animals had more than two
times higher Aif1 mRNA level (261%) compared to wild-
types after 24 h (Fig. 3a). Ethanol administration in-
creased the Aif1 mRNA levels in wild-type animals
(205%) 1 day after treatment, while no further increase
was observed in the ethanol-treated transgenic pups
(Fig. 3a). Morphological changes of microglial cells were
studied using IBA1 immunostaining which was evalu-
ated by deep learning methods. The highest proportions
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of resting microglial cells with highly ramified, fine pro-
cesses were detected in the brain of the untreated ani-
mals; however, there were some differences observed
between the wild-type and transgenic samples (Fig. 3b,
c). Control transgenic animals had significantly smaller
amounts of activated (intermediate and amoeboid) and
higher amounts of resting microglia in the thalamus,
and similar, albeit nonsignificant, changes were observed
in the other brain regions as well (Fig. 3c; see Table S3
for the statistical analysis of the proportion of activated
microglia). In contrast to saline treatment, 24 h after
ethanol administration, we detected a high proportion of
activated, hypertrophied microglia with increased cell
bodies and shorter, thicker processes in the striatum as
well as in the parietal and frontal parts of the cortex,
whereas amoeboid microglia were only present in a
smaller percentage in these areas. Contrarily, in the ret-
rosplenial and occipital cortical regions or in the thal-
amus and in the hippocampus, we found a particularly
high proportion of amoeboid microglia cells along with
Fig. 2 Gene expression analysis of inflammatory cytokines and glial activation markers in the brain. Relative expression of a Tnf, b Il1b, c Il6, d
Tgfb, e Il10, and f Il4 was studied in the brain of hHSPB1-overexpressing and wild-type mice 24 h after ethanol treatment using RT-PCR. Relative
expression was correlated with the wild-type control group (100%). Values are presented as mean ± SEM; n = 8 mice per group. Asterisk indicates
wild-type EtOH vs wild-type control group; plus sign indicates transgenic EtOH vs transgenic control group; hashtag indicates transgenic EtOH vs
wild-type EtOH group. Statistical analysis: 2-way ANOVA followed by Tukey post hoc test. *p < 0.05; ##p < 0.01; ###/+++p < 0.001
(See figure on previous page.)
Fig. 1 Transgene expression analysis in the brain. a hHSPB1 protein expression level was measured in whole-brain homogenates 24 h after ethanol treatment
using Western blot. Mouse β-actin was used as an internal control. b Quantification of the results was performed using the open-source ImageJ software. Fold
changes were correlated with the transgenic control group. Data are represented as mean ± SEM; n=3 mice per group. c Relative expression of the transgenic
hHSPB1 24 h after ethanol treatment was studied in the brain using RT-PCR. Fold changes were correlated with the transgenic control (nontreated) group.
Values are presented as mean ± SEM; n=8 mice per group. d hHSPB1 immunolabeling on sagittal brain sections of saline- and ethanol-treated transgenic
mice 24 h after treatment. Scale bar: 500 μm (Ctx, Hip) and 100μm (OCx and RSCx). Ctx cortex, Hip hippocampus, RSCx retrosplenial cortex, OCx occipital cortex.
e Fluorescent double immunohistochemistry on sagittal brain sections showing cell type–specific expression of the transgene in the cortical region. Scale bar:
20μm. Red: hHSPB1; green: IBA1/NEUN/GFAP; blue: DAPI
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the intermediate ones (Fig. 3b, c). The proportion of
intermediate and amoeboid microglia was significantly
higher in all brain areas of the ethanol-treated mice com-
pared to those of the control animals; however, the trans-
genic group showed a nonsignificant trend of increased
proportion of activated microglia compared to ethanol-
treated wild-type one (Fig. 3c). In parallel, the IBA1 cover-
age was more extensive in both ethanol-treated transgenic
and wild-type brains compared to control ones. This in-
crease in extent after ethanol treatment was more pro-
nounced in the transgenic animals with significant
differences in the frontal cortical, thalamic, and striatal re-
gions (Fig. 3d). To determine the characteristic features of
the activated microglia cells, we analyzed the expression of
M1 (pro-inflammatory) and M2 (anti-inflammatory)
phenotypic markers. In the case of M1 markers, only Cd68
showed notable changes; as in response to ethanol treat-
ment, a significant threefold increase (312%) was detected
in hHSPB1 transgenic animals, whereas only a slight in-
crease was observed in wild-type animals. Interestingly, the
level of the other M1 marker, the inducible nitric oxide syn-
thase (iNos), remained unchanged after treatment (Fig. 3e).
Similar changes were observed for M2 markers. One of the
markers, the mannose receptor C-type 1 (Mrc1), also
remained unchanged, while the other one, arginase 1
(Arg1), was nearly doubled in wild-type animals (186%) and
showed an even significantly higher, almost fourfold in-
crease (375%) in hHSPB1 transgenic animals after ethanol
treatment (Fig. 3e). One week after the treatment, micro-
glial cells returned to their resting state-like morphology
(Fig. S3a). Although Aif1 mRNA levels were approximately
the same in each group, 1 week after treatment, the IBA1-
covered area remained smaller in most brain areas of
ethanol-treated wild-type animals compared to those of the
control wild-type group (Fig. S2d and Fig. S3b).
Ethanol-induced activation of astrocytes in the brain of
hHSPB1-overexpressing mice
In the next step, we studied the mRNA expression levels
of Gfap and Vim, two intermediate filament proteins of
astrocytes used as markers of reactive astrogliosis. The
level of Gfap mRNA was increased 24 h after ethanol
treatment both in the wild-type and transgenic groups,
showing a fourfold increase in the transgenic group
(440%) and a twofold increase in the wild-type one
(196%, Fig. 4a). In contrast, the expression level of Vim
mRNA did not change in the wild-type group and only
slightly increased in the transgenic group in response to
ethanol treatment (Fig. 4a). The level of both markers
returned to the level of the control group 1 week after
the treatment (Fig. S2e-f). The expression pattern of
GFAP at the protein level and morphological changes of
astrocytes was studied using immunohistochemistry. No
significant change was detected in the morphology of
astroglia 24 h after ethanol treatment (Fig. S4a-b). One
week later, however, an increased GFAP immunoreactiv-
ity and hypertrophic astrocytes were detected in differ-
ent brain regions both in wild-type and transgenic mice
in response to ethanol treatment (Fig. 4b, c). Quantifica-
tion of the immunostained area revealed a strong en-
hancement in GFAP coverage throughout the brain 1
week after ethanol treatment. A significant difference be-
tween ethanol-treated wild-type and transgenic mice was
found in the striatum and in the parietal cortex (Fig. 4b).
Changes in the level of ethanol-induced apoptosis in
HSPB1-overexpressing transgenic mice
In order to detect programmed cell death in the
brain sections of mice, we analyzed the amount of
fragmented DNA using TUNEL assay. In the brain
of the control, saline-treated animals, a very low
level of apoptosis was observed, while the number of
TUNEL-positive cells was dramatically increased 24 h
after ethanol treatment (Fig. 5a). For quantitative
comparison, the TUNEL-positive cells were counted
in fifteen areas of each brain section of each group.
The statistical analysis revealed a significant increase
in the number of apoptotic cells in most of the stud-
ied brain regions following ethanol treatment. The
highest number of apoptotic cells was found in the
(See figure on previous page.)
Fig. 3 Activation of microglia 24 h after ethanol treatment in the brain of transgenic and wild-type mice. a Relative expression of Aif1 in the brain
of hHSPB1-overexpressing and wild-type mice 24 h after ethanol treatment. Relative expression was correlated with the wild-type control group
(100%). n = 8 mice per group. b Morphological changes of microglia 24 h after EtOH treatment on sagittal brain sections of hHSPB1-
overexpressing and wild-type mice. Microglia with different morphologies were visualized with IBA1 immunostaining using the peroxidase
method. Scale bar: 100 μm (OCx and Hip). c Proportions of IBA1+ microglia in different brain regions according to their morphology. d
Quantification of IBA1 immunoreactive areas. Results are given in percentage of the immunopositive areas compared to the outlined brain areas
(relative area). n = 3 mice per group, 3 sections per animal. e Relative expression of M1 microglia markers (Cd68, iNos) and M2 microglia markers
(Mrc1, Arg1) in the brain of hHSPB1-overexpressing and wild-type mice 24 h after ethanol treatment. Relative expression was correlated with the
wild-type control group (100%). n = 8 mice per group. Values are presented as mean ± SEM. Asterisk indicates wild-type EtOH group vs wild-type
control group; plus sign indicates transgenic EtOH group vs transgenic control group; hashtag indicates transgenic EtOH group vs wild-type EtOH
group; white triangle indicates transgenic control vs wild-type control group. Statistical analysis: 2-way ANOVA followed by Tukey post hoc test.
*/#/+/Δp < 0.05; **/##/++p < 0.01; ***/###/+++p < 0.001. Ctx cortex, Hip hippocampus, RSCx retrosplenial cortex, OCx occipital cortex, PCx parietal
cortex, FCx frontal cortex, Th thalamus, Str striatum
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cortex, thalamus, striatum, and midbrain, whereas a lower
level of apoptosis was detected in the hippocampus. In the
cerebellum, a high level of physiological cell death was vis-
ible, but the number of apoptotic cells remained similar
after ethanol treatment (Fig. 5b). Comparing wild-type
and hHSPB1-overexpressing animals, a slightly lower
number of apoptotic cells was found in the brain of the
transgenic animals; however, the difference was not statis-
tically significant (Fig. 5b).
These in vivo results (summarized in Fig. S9) served as a
basis for our subsequent in vitro experiments where we
aimed to characterize the specific cell type that could be
responsible for the aforementioned alteration of immune
regulation triggered by the overexpression of hHSPB1.
Fig. 4 Astrocyte activation after ethanol treatment in the brain of transgenic and wild-type mice. a Relative expression of Gfap and Vim in the
brain of hHSPB1-overexpressing and wild-type mice 24 h after ethanol treatment. Relative expression was correlated with the wild-type control
group (100%). n = 8 mice per group. b Astrocytes with different morphologies were visualized with GFAP immunostaining using the peroxidase
method 1 week after EtOH treatment. Quantification of GFAP immunoreactive areas: results are given in percentage of the immunopositive areas
compared to the outlined brain areas (relative area). n = 3 mice per group, 3 sections per animal. c Morphological changes of astrocytes 1 week
after EtOH treatment on sagittal brain sections of hHSPB1-overexpressing and wild-type mice. Scale bar: 500 μm. Values are presented as mean ±
SEM. Asterisk indicates wild-type EtOH group vs wild-type control group; plus sign indicates transgenic EtOH group vs transgenic control group;
hashtag indicates transgenic EtOH group vs wild-type EtOH group. Statistical analysis: 2-way ANOVA followed by Tukey post hoc test. */+p < 0.05;
**/##/++p < 0.01; ***/###/+++p < 0.001. Hip hippocampus, RSCx retrosplenial cortex, OCx occipital cortex, PCx parietal cortex, FCx frontal cortex, Th
thalamus, Str striatum
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Characterization of primary neuronal, astrocyte, and
microglial cell cultures derived from hHSPB1 and wild-
type mice
Primary neuron, astrocyte, and microglia cultures were
prepared from the brain of hHSPB1 transgenic animals
and from their wild-type littermates. First, the purity of
the primary cultures was assessed by fluorescent immu-
nohistochemistry, examining the presence of microglial
(IBA1), astrocyte (GFAP), and neuronal (MAP2)
markers. IBA1-GFAP double staining of the primary
microglia culture confirmed that its purity exceeded 93%
(Fig. 6a). We used the same double staining to deter-
mine the purity of the primary astrocyte culture, which
indicated that the microglia cells were present at the cell
culture at a proportion of 22% (Fig. 6b). The primary
neuronal culture was labeled with MAP2 and GFAP
Fig. 5 Apoptotic cell death detection using TUNEL assay 24 h after EtOH treatment. a Programmed cell death was detected on sagittal brain sections of control
and EtOH-treated hHSPB1-overexpressing and wild-type mice after 24 h of the respective treatment. Scale bar: 2000μm. b Apoptotic cells were counted in the
brain of transgenic and wild-type mice 24 h after EtOH treatment. Values are presented as mean ± SEM; n=6 mice per group. Asterisk indicates wild-type EtOH
group vs wild-type control group; plus sign indicates transgenic EtOH group vs transgenic control group. Statistical analysis: 2-way ANOVA followed by Tukey post
hoc test. */+p<0.05; **/++p<0.01; ***p<0.001. B whole brain, Ctx cortex, Hip hippocampus, Th thalamus, Str striatum, Mb midbrain, Cb cerebellum
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antibodies, which showed that more than 85% of the
cells were neurons in the culture (Fig. 6c). We also
analyzed the expression pattern of the transgene in the
primary cell cultures using hHSPB1-MAP2, hHSPB1-
GFAP, and hHSPB1-IBA1 fluorescent immunostainings.
The colocalization of the cell-specific markers with
hHSPB1 was similar to what was observed in the brain
sections earlier. We found that hHSPB1 colocalized with
MAP2 and GFAP, but was rarely detectable together
with IBA1, indicating that the transgenic hHSPB1 pro-
tein was mainly expressed by primary neurons and
astrocytes (Fig. 6d).
Effect of ethanol and cytokine treatment on the TNFα
production of primary neuron, astrocyte, and microglia
cultures
Primary cell cultures were treated with ethanol in order
to investigate the effect of alcohol on different cell types
of the brain. Ethanol can induce inflammatory processes
in the brain directly by itself and also by its metabolites
[33, 34], and it can also contribute to cerebral
inflammation indirectly by disrupting the integrity of the
blood-brain barrier, subsequently promoting the infiltra-
tion of peripheral immune cells to the brain [35]. Con-
sidering this affiliation of ethanol treatment with
inflammation, we also treated our model with pro-
inflammatory cytokines in order to model the inflamma-
tory milieu connected with the presence of ethanol. The
effective treatment concentrations of the cytokine and
ethanol were selected based on the data available in the
literature [21, 36] and on corresponding cell viability
measurements. We used a concentration of 50 mM etha-
nol for astrocytes and microglia cells and 200 mM for
neurons. During the cytokine treatment, the combin-
ation of 10 ng/ml human TNFα and 10 ng/ml human IL-
1β was applied to all cell types (see Supplementary ma-
terial and Fig. S5 for further details).
In order to analyze which cell type is the main source of
TNFα and to confirm whether hHSPB1 regulates cytokine
production in different brain-derived cells in our model,
we performed an enzyme-linked immunosorbent assay
(ELISA) assay specific against TNFα using the supernates
Fig. 7 Quantification of TNFα production of primary cell cultures. Twenty-four hours after EtOH and cytokine treatment, cell culture supernates
were collected. Concentrations of released TNFα (pg/ml) in the supernate of all the three isolated primary cell cultures were quantified using ELIS
A. TNFα concentrations were normalized to cell number of microglia and to RTCA values of astrocytes and neurons. crtl untreated control, EtOH
ethanol treatment, cyt cytokine treatment. Values presented are means ± SEM; n = 2–3. Asterisk indicates wild-type cytokine vs wild-type control
group; hashtag indicates transgenic cytokine vs transgenic control group; white triangle indicates transgenic cytokine vs wild-type cytokine
group. Statistical analysis: 2-way ANOVA followed by Tukey post hoc test. **/ΔΔp < 0.01; ###/ΔΔΔp < 0.001
(See figure on previous page.)
Fig. 6 Characterization of the established primary cell cultures. Evaluation of the purity of primary a microglia, b astrocyte, and c neuronal
cultures using fluorescent immunohistochemistry and detection of the presence of microglial (IBA1—green), astrocytic (GFAP—green/red), and
neuronal (MAP2—red) markers. Cell nuclei were counted for cell-specific markers and percentages compared to the total cell number are given.
Scale bar: 100 μm. Values are presented as mean ± SEM; n = 3–11. d Analysis of the expression pattern of the transgenic hHSPB1 protein in
primary cell cultures using double immunofluorescent staining. Scale bar: 50 μm. Green: hHSPB1; red: IBA1/MAP2/GFAP; blue: DAPI
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from primary cultures. The TNFα concentration values
were normalized to the corresponding cell viability mea-
surements: to cell number for microglia and to RTCA
values for astrocytes and neurons. Under control condi-
tions, TNFα was detectable in the highest proportion in
the supernates of glial cells. Microglial cells had almost
three times higher basal expression of TNFα (TG group:
283 pg/ml; Wt group: 351 pg/ml; columns 1–6, Fig. 7)
compared to astrocytes (TG group: 95 pg/ml; Wt group:
126 pg/ml; columns 7-12, Fig. 7), indicating that microglia
are the primary source of TNFα in the brain. Cytokine
treatment significantly increased the release of TNFα from
hHSPB1-expressing transgenic microglial cells compared
to nontreated transgenic cells (from 283 to 540 pg/ml).
However, no such effect was observed in wild-type micro-
glia. This indicates that the overexpression of hHSPB1
might modulate the release of TNFα since microglia from
hHSPB1 transgenic animals expressed a significantly
higher level of TNFα after cytokine treatment than the
cytokine-treated wild-type group (540 pg/ml and 266 pg/
ml, respectively; Fig. 7). Contrarily, after cytokine treat-
ment, TNFα production was significantly higher in wild-
type astrocytes compared to the control group; however, it
remained unchanged in the hHSPB1 transgenic cells
resulting in a significant difference between the two geno-
types upon cytokine treatment (WT: 184 pg/ml and TG:
120 pg/ml, respectively; Fig. 7). Surprisingly, ethanol treat-
ment only did not elicit a response from either glial cell
type (Fig. 7). In the supernates of primary neurons, a very
low TNFα presence was observed under control condi-
tions (Fig. 7), and no change was seen in response to the
various treatments.
Effect of cytokine and ethanol treatments on extracellular
and intracellular hHSPB1 levels
To determine whether extracellular or intracellular
hHSPB1 elicits the proposed inflammation-regulating ef-
fects, we examined the level of hHSPB1 protein in the
cell culture supernates by ELISA and in the cells by im-
munohistochemistry. The results of the human HSPB1
ELISA showed that no detectable amount of hHSPB1
was released by any of the analyzed cell types, upon
treatment or under control conditions (Fig. S6). As
microglial cells did not express an appreciable amount
of intracellular hHSPB1 even after treatment (Fig. S7),
we analyzed the changes in the intracellular level of the
transgenic protein only in primary astrocytes and neu-
rons. We found that the expression level of the trans-
gene within primary neurons and astrocytes was
influenced by the different treatments. In the case of pri-
mary neurons, the size of the MAP2-positive area was
not altered by cytokine treatment, while it was signifi-
cantly reduced by the ethanol treatment in both trans-
genic and wild-type neuronal cultures (to 41% and 46%,
respectively) (Fig. 8a, b, Fig. S8a-b). In HSPB1 transgenic
neurons, the fluorescence intensity corresponding to
hHSPB1 remained unchanged after ethanol treatment,
whereas it showed a moderate, but not significant in-
crease after the cytokine treatment (Fig. 8a, c). In astro-
cyte cells, treatment with cytokines or ethanol elevated
the intracellular GFAP levels. The cytokine treatment re-
sulted in a significant increase in GFAP intensity in both
transgenic and wild-type cells (to 138% and to 131%, re-
spectively), whereas after the exposure to ethanol, a sig-
nificant change was detected only in the transgenic
astrocytes (136 %), but not in wild-type ones (Fig. 8d, e,
Fig. S8c-d). In transgenic astrocytes, the level of hHSPB1
expression elevated significantly to 475% well above the
control’s baseline expression after cytokine treatment
and up to 205% after the ethanol treatment (Fig. 8d, f).
Discussion
The neuroprotective role of HSPB1 in both acute and
chronic neurodegenerative disorders has been previously
demonstrated by multiple research groups including
ours [20, 37, 38]. In parallel, a number of studies, using
either mouse models of peripheral inflammation or cell
cultures, revealed the regulatory function of HSPB1 in
inflammation. In these studies, HSPB1 was affiliated with
either pro- or anti-inflammatory functions in a context-
dependent manner [2]. By expanding our knowledge on
HSPB1 function as an immunoregulatory factor, it could
become a potential therapeutic target for fine-tuning
neuroinflammation, which is a common pathological
characteristic of most neurological disorders. Therefore,
in the present study, we investigated the immunoregula-
tory role of hHSPB1 in neuroinflammation using our
previously established hHSPB1-overexpressing mouse
model, as well as using primary cell cultures isolated
from the brain of these transgenic animals.
The brain is extremely sensitive to the cytotoxic effect
of ethanol during synaptogenesis, the period of brain de-
velopment when it undergoes rapid growth. Neurons are
vulnerable to ethanol-induced damage at this period to
such an extent that even a single day of alcohol treatment
can lead to neurodegeneration in the brain. Ikonomidou
and colleagues [21] demonstrated that maintaining the
blood ethanol concentration in 7-day-old rat pups above a
toxic threshold (200mg/dl) for at least 4 h triggers apop-
totic cell death detectable 24 h after the treatment. Besides
apoptosis, acute ethanol overdose has been demonstrated
to trigger microglia and astrocyte activation in different
animal models, so it is also suitable for investigating neu-
roinflammation [39]. Therefore, in this study, the same ex-
perimental arrangement was used to induce brain damage
in wild-type and hHSPB1-overexpressing transgenic mice.
In our transgenic animals, the human HSPB1 gene expres-
sion is driven by a cytomegalovirus (CMV) promoter. It is
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usually referred to as a constitutively active promoter;
however, it has been shown to be upregulated in vitro
under certain stress or inflammatory conditions [40–42].
Accordingly, increased transgene expression was observed
in response to ethanol treatment in different brain regions
of our transgenic mice and in the primary cells as well.
Several previous studies have demonstrated that HSPB1 is
upregulated upon neurological disorders; therefore, we
used this transgenic strain to model the role of HSPB1 in
neuroinflammation. Moreover, the expression pattern of
hHSPB1 protein in this transgenic model is similar to the
one that physiologically occurs in the human brain, as the
hHSPB1 protein was found to be synthesized in astrocytes
and neurons; however, hHSPB1-positive microglia were
rarely detected [43].
Consistent with previous data, our results confirmed
that even a single day of ethanol treatment is able to
induce high level of apoptosis accompanied by glial cell
activation and cytokine production in the developing
brain. The presence of hHSPB1 in transgenic animals in
itself did not influence the gene expression level of pro-
inflammatory cytokines remarkably. However, hHSPB1
overexpression in combination with ethanol treatment
resulted in a significantly higher increase in the level of
pro-inflammatory cytokines compared to those observed
in ethanol-treated wild-type mice 24 h after ethanol in-
jection, whereas the level of anti-inflammatory cytokines
remained unchanged. These results indicate that
hHSPB1 overexpression intensifies the expression of
pro-inflammatory cytokines in vivo following acute etha-
nol treatment.
Pro-inflammatory cytokines are produced in the brain
by various cells, such as microglia. At the same time, cyto-
kines affect microglia resulting in their further activation.
Upon different immunological stimuli and neuronal injur-
ies, microglia show an immediate response leading to
altered morphology and function. These activated micro-
glia cells are implicated in the protection of brain tissue by
cleaning cellular debris via phagocytosis, and in inflamma-
tory processes as well [39]. Immunostaining with IBA1
antibody clearly showed that the activation of microglia
takes place within 24 h after a single day of ethanol treat-
ment, as the size of IBA1-positive areas and the propor-
tion of activated microglia cells increased significantly in
all brain regions in response to ethanol. Ethanol-treated
hHSPB1 mice showed significantly greater IBA1 coverage
in certain brain areas than their wild-type littermates, with
a nonsignificant trend towards higher proportion of acti-
vated microglia. Interestingly, we found differences in the
control groups as well, since the thalamus of control
transgenic animals showed a significantly higher amount
of ramified microglia and lower IBA1 immunoreactivity
compared to that of wild-type ones. Our immunohisto-
chemistry data seems to contradict the result of the RT-
PCR experiments, where we found a higher gene expres-
sion of Aif1 in the control transgenic vs wild-type group,
while it did not show a further increase in the transgenic
animals in response to ethanol treatment. This discrep-
ancy could be derived from the different samplings in the
two experiments: in the immunostaining, we analyzed cer-
tain brain regions separately, while mRNA was isolated
from the whole-brain homogenates for the RT-PCR study.
Following brain injury, activated microglia move rapidly
towards the damaged neurons leading to a remarkable in-
crease in the local microglial density [44]. Therefore, it
could be possible that Aif1 expression is overall invariable
in the brain while there are local differences in certain
brain regions, similarly what we found in the brain of the
transgenic animals at the protein level with and without
ethanol treatment. The alterations in the nontreated
group could be the result of the fact that HSPB1 is in-
volved in neurodevelopment, contributing to neuronal dif-
ferentiation and angiogenesis [45]. However, when
examining the effect of ethanol treatment, we must ac-
knowledge that activated microglia could play a complex
and, in many cases, context-dependent role in the dam-
aged nervous system, as they can contribute to both
pathological and reparative processes. Recent studies
showed that the depletion of microglia was able to block
the expression of ethanol-induced pro-inflammatory fac-
tors [46, 47], whereas other groups found that the elimin-
ation of microglia exacerbated neuronal damage and
augmented pro-inflammatory processes after ischemic
brain injury [48–50]. In our study, although higher IBA1
immunoreactivity and higher pro-inflammatory cytokine
expression were found in ethanol-treated transgenic ani-
mals compared to their wild-type littermates, there was no
concomitant increase in neuronal loss, suggesting that
(See figure on previous page.)
Fig. 8 Effects of cytokine and EtOH treatment on intracellular hHSPB1, MAP2, and GFAP levels in transgenic cultures. a hHSPB1 and MAP2 double
immunofluorescence staining in primary neuronal culture from hHSPB1-overexpressing mice 24 h after EtOH and cytokine treatment. Scale bar:
200 μm. Red: MAP2; green: hHSPB1; blue: DAPI. b Quantification of MAP2-positive area in transgenic primary neurons. n = 12. c Quantification of
hHSPB1 fluorescent intensity in transgenic primary neurons. n = 12. d hHSPB1 and GFAP double immunofluorescence staining in primary
astrocyte culture from hHSPB1-overexpressing mice 24 h after EtOH and cytokine treatment. Scale bar: 50 μm. Red: GFAP; green: hHSPB1; blue:
DAPI. e Quantification of GFAP fluorescent intensity in transgenic primary astrocytes. n = 9–12. f Quantification of hHSPB1 fluorescent intensity in
transgenic primary astrocytes. n = 10–11. Data are expressed as a percentage of untreated cells. Values presented are means ± SEM. crtl untreated
control, EtOH ethanol treatment, cyt cytokine treatment. Statistical analysis: unpaired two-tailed t test. *p < 0.05; ***p < 0.001 compared to control
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hHSPB1 overexpression may induce diverse or even op-
posite microglial functions. Therefore, we examined the
expression of markers corresponding to M1/M2 micro-
glial polarization and we found that, in response to
ethanol treatment, hHSPB1 overexpression enhanced
the presence of both microglial phenotypes, since the
M2 microglia marker Arg1 and the M1 marker Cd68
were also significantly higher in transgenic animals
compared to wild-type ones. However, the remarkably
high expression of pro-inflammatory cytokines demon-
strated that M1 (pro-inflammatory) microglia predomi-
nated in hHSPB1 transgenic animals 1 day after ethanol
treatment. After ethanol-induced brain injury, micro-
glial recovery could be important in promoting neuro-
genesis leading to functional recovery [51, 52]. One
week after the ethanol treatment, IBA1-stained micro-
glia have recovered their highly ramified processes
throughout the brain, accompanied by the decrease of
cytokine expression to the normal level. It seems that
in the ethanol-treated wild-type animals, microglial re-
covery could not take place within 1 week, while the
level of IBA1 was almost equal in the transgenic groups
with or without ethanol treatment.
Astrocytes, the other key cells in neuroinflammation,
are special glial cells that have many essential functions
in the brain. They respond to different forms of brain in-
juries through a process called reactive astrogliosis,
which has different stages, according to the severity of
the injury [53]. The morphological transformation of as-
trocytes and glial scar formation are partly controlled by
pro- and anti-inflammatory cytokines [44]. As ethanol
treatment triggered a rapid increase in cytokine expres-
sion and microglia activation in our experiment, it is not
surprising that Gfap mRNA level was also elevated 24 h
after treatment, showing significantly higher expression
in ethanol-treated transgenic animals compared to
ethanol-treated wild-type ones. However, no substantial
changes were found neither in the morphology of the as-
trocytes nor in the GFAP coverage on the first day after
injection. Instead, a remarkable expansion of GFAP-
stained cells was observed 1 week later, corresponding
with earlier studies showing that the formation of
GFAP-positive filaments is a slower process. Moreover,
GFAP staining around the blood vessels was also aug-
mented in response to ethanol, especially in hHSPB1-
overexpressing transgenic brains, leading to a significant
difference in the percentage of GFAP-covered area be-
tween the two genotypes in certain brain regions. We
also studied the inflammatory processes in primary
astrocyte cultures in which astrocyte activation was ob-
served, as we detected a pronounced GFAP upregulation
within the cells in response to cytokine and ethanol
treatments. Astrocytes can have a multitude of functions
in the brain; thus, the remarkably high astrocytic
hHSPB1 expression in the present study could poten-
tially modulate these functions and could be key in
understanding our observations. HSPB1 has been shown
to interact with GFAP and to assist the proper
organization of the filament network in astrocytes, which
potentially contribute to the maintenance of normal
astrocyte function [12]. Furthermore, strong colocaliza-
tion of HSPB1 with cleaved caspase-3 in reactive astro-
cytes could promote astroglial survival [54]. HSPB1 may
not only have positive effects in glial cells but can also
be beneficial for the surrounding damaged tissue [55].
For example, Bechtold and Brown [56] raised the possi-
bility of a synaptic transfer of HSPB1 from glial cells to
neurons under stress conditions. In addition, presynaptic
localization of HSPB1 in astrocytes could also promote
neuronal survival via the restoration of synaptic activity
after stress stimuli [56].
We also analyzed which cell type of the brain tissue
could be responsible for the highly elevated levels of
pro-inflammatory cytokines in hHSPB1 transgenic mice.
Our in vitro results demonstrated that microglia are the
primary TNFα-producing cell type under inflammatory
conditions. In terms of astrocytes, both wild-type and
transgenic cells had a basal TNFα production, which in-
creased after cytokine treatment in the wild-type culture,
but not in the transgenic one. Considering that HSPB1
was previously shown to interact with Annexin A1 and
thereby lower the release of TNFα in reactive astrocytes
[17, 57], it is possible that the greatly elevated level of
intracellular hHSPB1 in astrocytes may directly affect
their TNFα production. The observation that ethanol
treatment did not induce TNFα release in glial cultures
may be explained by the fact that the inflammation-
inducing effect of ethanol is partly related to neuronal
damage. For example, in the brain of adult rodents,
which are less sensitive to the harmful effects of ethanol
compared to fetuses, only a low degree of neurodegener-
ation or decline in neurogenesis was observed and, in
parallel, no significant changes in protein levels of pro-
inflammatory cytokines were detected [22, 58]. On the
other hand, the effects of ethanol are potentiated by its
metabolites: acetaldehyde had a greater impact on astro-
cyte and oligodendrocyte cultures than ethanol [59, 60].
Overall, these findings are in accordance with previous
studies, in which activated microglia were identified as
the main source of pro-inflammatory cytokines, whereas
TNFα production by astrocytes was lower even after ac-
tivating stimuli [61, 62]. We consider the use of serum
for the culture of our primary cells as a limitation of our
study because of potential priming effects. We should
note that based on our present results as well as litera-
ture data, primary astro- and microglia cells despite be-
ing exposed to serum showed low expression of
inflammatory mediators and activation markers [63, 64].
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It is very interesting that, after cytokine treatment,
microglia from hHSPB1 transgenic animals were seem-
ingly in a further increased inflammatory status by se-
creting a higher amount of TNFα than wild-type cells,
although microglia did not express appreciable amount
of the transgene. This finding suggests a potential indir-
ect effect of hHSPB1 on microglia activation. Based on
previous data, not only the initial microglia response can
affect the subsequent astrocyte activation, but microglial
function could also depend on the crosstalk with astro-
cytes. For example, NFκB-mediated astrocytic expression
of WNT induces microglia proliferation or the ATP re-
leased from astrocyte can act on the purinergic receptors
of microglia with concomitant induction of Ca2+ signal-
ing and IL-1β containing vesicula formation [65–68].
Astrocytes can also mediate microglial function and dis-
tribution by secreting a plethora of inflammatory cyto-
kines and chemokines or through direct cell-cell
interactions [69–71]. Therefore, we hypothesize that ele-
vated intracellular hHSPB1 levels in astrocytes remaining
in microglial cultures could have an effect on the release
of these factors, contributing to the increased microglial
activation. HSPB1 has been demonstrated to regulate
several signaling cascades, such as inflammation-
associated NFκB or p38 mitogen–activated protein kin-
ase (MAPK) pathways; therefore, it could modulate the
expression of numerous factors. Intracellular HSPB1 was
also shown to induce the transcription of inflammatory
mediators by participating in the stabilization of their
mRNA [72]. In addition, astrocyte cell culture treated
with HSPB1 exhibited an increased level of IL-8 and de-
creased production of TGF-β1 and CD40 ligand [16].
However, based on these findings, it would be of interest
to fully elucidate the activation circuit between astro-
cytes and microglia in hHSPB1-overexpressing mice.
These results clearly demonstrate that the overexpres-
sion of hHSPB1 protein promotes glial activation and
cytokine response upon acute ethanol treatment. Despite
that HSPB1 was previously seen as an anti-inflammatory
factor, our observation is in accordance with a growing
number of evidence suggesting a more complicated,
context-dependent role for this protein in inflammation
[73]. An earlier report using HeLa cells showed that
HSPB1 is associated with the expression of pro-
inflammatory factors and involved in the IL-1 and TNF-
induced signaling [72]. In C6 glioma cells, the chaperone
activity of HSPB1 contributed to the production of the
pro-inflammatory cytokine, IL-6, whereas T cells from
HSPB1−/− mice exhibited reduced secretion of TNF and
IL-2 [74, 75]. Recombinant HSPB1 treatment also re-
sulted in enhanced pro-inflammatory cytokine expres-
sion in vitro [18, 76, 77]. Although the majority of the
literature describes extracellular heat-shock proteins as
regulators of inflammation, we could not detect hHSPB1
in the supernates of the primary cell cultures in our ex-
periments. Thus, it is reasonable to suspect that the
intracellular form of the protein is the major source of
inflammation modulation in this scenario.
In order to learn more about the overall outcome of
the amplified pro-inflammatory cytokine production in
hHSPB1-overexpressing mice, ethanol-induced cell
death was studied using TUNEL assay. In the brain of
the control, saline-treated animals, the low extent of
apoptosis could correspond to the physiological, pro-
grammed cell death occurring in the developing brain
[21]. However, even a single day of ethanol treatment
dramatically increased the number of apoptotic cells in
most of the studied brain areas. The observed differ-
ences between the brain regions were corresponding to
their previously described susceptibility to alcohol-
induced cell death and to their described sensitivity to
alcohol in different developmental stages [21]. Intri-
guingly, despite the remarkably high level of Tnf, we
found a slightly lower amount of TUNEL-positive apop-
totic cells in the brains of hHSPB1 animals compared
with those of wild-types after ethanol treatment. TNFα
is a described inducer of apoptosis in the nervous system
acting in a dose-dependent manner [78–80]. On the
other hand, numerous in vivo and in vitro studies
proved that HSPB1 contributes to the prevention of
neuronal cell death [81–84]. Previously, we demon-
strated the protective effects of hHSPB1 on neurons
after both acute and chronic ethanol treatment in adult
mice [37]. The neuroprotective effect of the enhanced
intracellular hHSPB1 could partly be based on its ability
to interact with neurofilaments and with the actin net-
work, and by this supporting the structural integrity of
neurons [85, 86]. HSPB1 can also affect the TNFα-
induced cell death. HSPB1 prevented TNFα-mediated
apoptosis by modulating cellular glutathione levels [87],
by mediating the activity of NFκB [88, 89], or the p38/
extracellular signal-regulated kinase (ERK) signaling path-
ways [90]. Furthermore, HSPB1 was shown to prevent
caspase-mediated apoptosis, which can also be initiated by
TNFα [91, 92]. Based on these observations, we assume
that the elevated level of hHSPB1 could compensate the
apoptosis-inducing effect of the highly increased Tnf in
the hHSBP1-overexpressing mice. Moreover, it is worth
mentioning that elevated levels of pro-inflammatory
cytokines in the nervous system can also have benefi-
cial effects. For example, depending on the target re-
ceptor it acts on, TNFα can be involved in
demyelination as well as in neuronal regeneration,
whereas neurotrophic factors were found to be upreg-
ulated after acute IL-1β administration [93, 94]. Fur-
thermore, it has been recently discovered that chronic
IL-1β and TNFα treatment activates an astrocyte
phenotype that supports neuronal viability [95].
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Conclusions
Taken together, our work provides in vivo evidence that
hHSPB1 overexpression is associated with enhanced
pro-inflammatory response in a mouse model of
ethanol-induced acute neuroinflammation. Notably,
hHSPB1 overexpression modulated the inflammatory
processes evoked by ethanol resulting in higher expres-
sion of pro-inflammatory cytokines and increased glial
cell activation. The findings presented here could shed
light on an unknown balancing role of hHSPB1 in in-
flammation regulation as the increased inflammation in
the hHSPB1-overexpressing mice was not accompanied
by increased neuronal damage. Thus, the data presented
by this study could help to understand the potential
regulatory role of hHSPB1 in neuroinflammation.
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